Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates
Portfolio Pulse from
Alnylam Pharmaceuticals (ALNY) reported a quarterly earnings of $0.06 per share, surpassing the Zacks Consensus Estimate of a loss of $0.21 per share. This marks a significant improvement from the loss of $1.10 per share a year ago.
February 13, 2025 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals reported better-than-expected Q4 earnings of $0.06 per share, significantly improving from a loss of $1.10 per share a year ago.
The positive earnings surprise and significant improvement from the previous year's loss are likely to boost investor confidence and positively impact ALNY's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100